Cargando…
Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study
INTRODUCTION: Consideration of patient preferences for guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) may help improve major gaps in prescribing and adherence. This study aimed to identify the range and relative priority of factors influencing pa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667168/ https://www.ncbi.nlm.nih.gov/pubmed/33204073 http://dx.doi.org/10.2147/PPA.S276328 |
_version_ | 1783610251277238272 |
---|---|
author | Trinkley, Katy E Kahn, Michael G Allen, Larry A Haugen, Heather Kroehl, Miranda E Lin, Chen-Tan Malone, Daniel C Matlock, Daniel D |
author_facet | Trinkley, Katy E Kahn, Michael G Allen, Larry A Haugen, Heather Kroehl, Miranda E Lin, Chen-Tan Malone, Daniel C Matlock, Daniel D |
author_sort | Trinkley, Katy E |
collection | PubMed |
description | INTRODUCTION: Consideration of patient preferences for guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) may help improve major gaps in prescribing and adherence. This study aimed to identify the range and relative priority of factors influencing patients’ decisions to take HFrEF medications. MATERIALS AND METHODS: This was a convergent mixed methods study of patients with HFrEF. Focus groups were conducted to identify a list of factors followed by individuals rating and ranking the influence of each factor on their decision to take a medication. Using thematic analysis, we summarized preferences into categories. RESULTS: Two focus groups with 13 participants reported 22 factors. Of the factors, “keeping you alive” was most commonly ranked in the top three (seven participants), followed by “communication and understanding” (six participants). Factors were summarized into six categories (listed in order of patient-reported influence): 1) demonstrated improvements in quality of life and longevity, 2) decreased risk of hospitalization, 3) opportunity for shared decision-making and trust in provider, 4) absence of adverse events, 5) affordability, and 6) convenience of taking and absence of interference with daily life. CONCLUSION: Patients prioritize treatment benefits and being informed more than risks, cost and inconvenience of taking HFrEF medications. |
format | Online Article Text |
id | pubmed-7667168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-76671682020-11-16 Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study Trinkley, Katy E Kahn, Michael G Allen, Larry A Haugen, Heather Kroehl, Miranda E Lin, Chen-Tan Malone, Daniel C Matlock, Daniel D Patient Prefer Adherence Original Research INTRODUCTION: Consideration of patient preferences for guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) may help improve major gaps in prescribing and adherence. This study aimed to identify the range and relative priority of factors influencing patients’ decisions to take HFrEF medications. MATERIALS AND METHODS: This was a convergent mixed methods study of patients with HFrEF. Focus groups were conducted to identify a list of factors followed by individuals rating and ranking the influence of each factor on their decision to take a medication. Using thematic analysis, we summarized preferences into categories. RESULTS: Two focus groups with 13 participants reported 22 factors. Of the factors, “keeping you alive” was most commonly ranked in the top three (seven participants), followed by “communication and understanding” (six participants). Factors were summarized into six categories (listed in order of patient-reported influence): 1) demonstrated improvements in quality of life and longevity, 2) decreased risk of hospitalization, 3) opportunity for shared decision-making and trust in provider, 4) absence of adverse events, 5) affordability, and 6) convenience of taking and absence of interference with daily life. CONCLUSION: Patients prioritize treatment benefits and being informed more than risks, cost and inconvenience of taking HFrEF medications. Dove 2020-11-10 /pmc/articles/PMC7667168/ /pubmed/33204073 http://dx.doi.org/10.2147/PPA.S276328 Text en © 2020 Trinkley et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Trinkley, Katy E Kahn, Michael G Allen, Larry A Haugen, Heather Kroehl, Miranda E Lin, Chen-Tan Malone, Daniel C Matlock, Daniel D Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study |
title | Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study |
title_full | Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study |
title_fullStr | Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study |
title_full_unstemmed | Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study |
title_short | Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study |
title_sort | patient treatment preferences for heart failure medications: a mixed methods study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667168/ https://www.ncbi.nlm.nih.gov/pubmed/33204073 http://dx.doi.org/10.2147/PPA.S276328 |
work_keys_str_mv | AT trinkleykatye patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy AT kahnmichaelg patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy AT allenlarrya patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy AT haugenheather patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy AT kroehlmirandae patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy AT linchentan patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy AT malonedanielc patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy AT matlockdanield patienttreatmentpreferencesforheartfailuremedicationsamixedmethodsstudy |